Wondering how the US markets performed one hour before the close of the markets on Friday? Discover the movers and shakers of today's session in our comprehensive analysis.
The Data Monitoring Committee (DMC) recommended stopping the EMBOLD study ahead of schedule after the interim analysis demonstrated strong positive outcomes.
As the regular session of the US market concludes on Thursday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.
The biotech sector is currently experiencing a robust rally, a significant turnaround from a period of subdued performance. This resurgence is primarily fueled by a wave of promising drug trial results that are validating extensive research and development efforts across the industry. Investors are demonstrating a renewed appetite for risk,
Wall Street boosted the stock’s price targets after the company’s late-stage trial for its essential tremor drug, ulixacaltamide, delivered strong efficacy and safety data.
